Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant-Reference-Cited by-同舟云学术

Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant

Published:2012-01 Issue:1 Volume:14 Page:7-11
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Sili Uluhan,Leen Ann M.,Vera Juan F.,Gee Adrian P.,Huls Helen,Heslop Helen E.,Bollard Catherine M.,Rooney Cliona M.

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics(clinical),Oncology,Immunology,Immunology and Allergy

Reference20 articles.

1. Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantation;Leen;Expert Opin Biol Ther,2010

2. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation;Myers;Bone Marrow Transplant,2007

3. Adenoviral infections in hematopoietic stem cell transplantation;Leen;Biol Blood Marrow Transplant,2006

4. Cytotoxic T lymphocytes as immune-therapy in haematological practice;Leen;Br J Haematol,2008

5. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals;Leen;Nat Med,2006

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Facing challenges with hope: universal immune cells for hematologic malignancies;Cancer Biology & Medicine;2023-05-04

2. Generation of good manufacturing practice grade virus-specific T cells for the management of post-transplant CMV infections;Journal of Immunological Methods;2022-12

3. Combining CD34 + stem cell selection with prophylactic pathogen and leukemia directed T‐cell immunotherapy to simultaneously reduce graft versus host disease, infection, and leukemia recurrence after allogeneic stem cell transplant;American Journal of Hematology;2022-05-20

4. In-situ scalable manufacturing of Epstein–Barr virus-specific T-cells using bioreactor with an expandable culture area (BECA);Scientific Reports;2022-04-29

5. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT;Blood Advances;2022-04-19